Cutting Edge Firm CEO on Alzheimer’s in Focus in Nerve Regeneration Research
INTERVIEW ON THE PRICE OF BUSINESS SHOW, MEDIA PARTNER OF THIS SITE.
Recently Kevin Price, Host of the nationally syndicated Price of Business Show, interviewed Paul Brennan .
“Over the last 15 years there has been a distinct failure in the development of effective treatments for Alzheimer’s disease (AD),” reports Technology Networks. “As the incidence of AD continues to rise, the medical community and pharmaceutical industry are now exploring novel technologies that target molecular pathways outside of the amyloid-β hypothesis. One example is the regenerative medicine company NervGen, who recently announced it was advancing its therapeutic technology platform, currently in development for spinal cord injury and multiple sclerosis, to create new treatments for AD.”
According to a company statement, “The technology platform, NVG-291, targets sites of inflammatory damage and removes inhibition of a protein implicated in endogenous repair. Paul Brennan, President, CEO & Director, NervGen Pharma, has over 30 years of experience in the pharmaceutical and biotech industries, which was a focus of the discussion on a recent Price of Business show with Kevin Price how the company’s compound, NVG-291, can address Alzheimer’s disease, multiple sclerosis and spinal cord damage.”
LISTEN TO THE INTERVIEW IN ITS ENTIRETY HERE:
The Price of Business is one of the longest running shows of its kind in the country and is in markets coast to coast. The Host, Kevin Price, is a multi-award winning author, broadcast journalist, and syndicated columnist. Learn more about the show and its digital partners at www.PriceofBusiness.com (scroll down to the bottom of the page).
About Author
